{
    "2020-05-09": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Eli Lilly's $8 Billion Oncology Bet Gets Its Chance to Succeed",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Oncology",
                        "Bet",
                        "Succeed"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Lilly Receives U.S. FDA Approval for Retevmoâ„¢ (selpercatinib), the First Therapy Specifically for Patients with Advanced RET-Driven Lung and Thyroid Cancers",
                "features": {
                    "keywords": [
                        "Lilly",
                        "FDA",
                        "Approval",
                        "Retevmo",
                        "Therapy",
                        "Cancer"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}